Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mobile phones

This article was originally published in The Gray Sheet

Executive Summary

Cellular Telecommunications Industry Association and FDA's device center ink a three-year cooperative R&D agreement June 8 that will facilitate third-party research on mobile phones as potential health hazards. Under the CRADA, an "organizing committee" of staff from CDRH and other agencies will oversee genotoxity and epidemiology studies intended to confirm earlier findings by Wireless Technology Research, LLC and assess the need for further research. CTIA will fund the research and cover FDA travel expenses

You may also be interested in...



CDC NIOSH Studies To Evaluate RF Effect On Cell-Growth Substance

The Centers for Disease Control and Prevention's National Institute for Occupational Health and Safety (NIOSH) is planning to evaluate ornithine decarboxylase (ODC), a substance associated with human cell growth induced by carcinogens.

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel